Blog

Company News

Industry Trends

Laws Regulations

All Categories >

21

2023-09

Issue 1 | Sharing of CAR Positive Rate Testing Data

In 2010, two patients with hematologic malignancies became the first participants in a clinical trial of CAR-T cell therapy at the Perelman School of Medicine at the University of Pennsylvania, and their cancers achieved complete remission that same year. More than a decade later, research published in Nature and based on up to 10 years of follow-up data indicate that CAR-T cells can still be detected in patients’ bodies 10 years after infusion. Owing to their high selectivity, localized high concentrations, and customizable nature, cell therapies have ushered in a new chapter in cancer immunotherapy.

2023-09-21

He Yousheng

08

2023-09

Themed Salon | Antibody Discovery: The First Step in Developing Novel Antibody Drugs

Antibody therapeutics currently represent the fastest-growing segment within the biopharmaceutical industry and are a major focus of global drug discovery and development. This rapid advancement is driven by technological innovations, including diverse display technologies, transgenic humanized animal models, single-cell PCR, and single-cell sequencing.

2023-09-08

He Yousheng

17

2023-08

Hycells Services | “True” Viral Neutralizing Antibody Testing

Currently, pseudovirus-based assays closely mimic physiological infection mechanisms and can largely replicate the in vivo therapeutic efficacy; however, there is a substantial discrepancy between neutralization assay results obtained with live viruses and those obtained with pseudoviruses. Therefore, live-virus neutralization assays are an indispensable component of antiviral drug and vaccine development.

2023-08-17

He Yousheng

16

2023-08

Anti-FMC63 Antibody | Precise Support for CD19 CAR Cell Therapy Research

CD19 is currently the most widely used target in CAR-T cell therapy, and numerous studies have demonstrated that CD19 is an effective and safe target for the treatment of B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and B-cell lymphomas. FMC63 is a murine monoclonal antibody that targets human CD19. To date, the majority of reported CAR-T clinical trials have constructed CAR-T cells based on the FMC63 antibody sequence, including the two FDA-approved anti-CD19 CAR-T cell therapies, Kymriah and Yescarta. According to the “Research Guidelines on Quality Control Testing and Nonclinical Considerations for CAR-T Cell Therapy Products” issued by the National Institute for Food and Drug Control in 2018, flow cytometry should be used to assess CAR transduction positivity, with preference given to antigen-specific proteins or anti-idiotypic antibodies that exhibit superior specificity for the antigen-binding site.

2023-08-16

He Yousheng

16

2023-08

Hycells Launches a Groundbreaking Product | γδ T (Vγ9Vδ2-T) Cell Expansion Kit

γδ T cells represent an emerging frontier in tumor immunology; like αβ T cells, they can exert cytotoxic effector functions (ADCC) and produce pro-inflammatory cytokines. The key distinction is that γδ T cells recognize tumor antigens in an MHC-unrestricted manner, endowing them with the characteristics of a universal cell therapy product. The TCRγδ on the surface of γδ T cells does not require binding to MHC molecules or antigen presentation by antigen-presenting cells (APCs); instead, it can directly recognize and bind antigenic molecules. However, the repertoire of TCRγδ variants is limited and lacks diversity, resulting in a relatively narrow antigen-recognition spectrum for γδ T cells. γδ T cells in different tissues express distinct TCRγδ receptors and recognize antigens with varying properties, whereas γδ T cells within the same tissue typically express the same TCRγδ and recognize antigens of the same type.

2023-08-16

He Yousheng

21

2023-07

Exhibition Recap | Hycells Biotechnology Launches Multiple New Products at IBI EXPO 2023

Biologics innovation drugs have become a fiercely contested frontier in the biopharmaceutical industry, and a comprehensive, mature supply chain is indispensable for the sector’s development. With global supply chains still vulnerable, domestic substitution in CDMO services and supply-chain components has emerged as a new perspective on translating research outcomes into commercial value for many companies in this space. Against this pharmaceutical landscape, the IBI EXPO 2023 International Biologics Innovation Drug Industry Conference was launched, taking place from July 13 to 15 at the Shanghai Multinational Procurement Exhibition Center. As a pioneer in domestic substitution, Heyou Bio was also invited to participate in this event.

2023-07-21

He Yousheng
< 1...141516...18 >